Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

Sprint Fidelis Wire Defibrillator Lead Failure

Recall Has Patients Wondering Whether to Have Wire Leads Removed

Following a October 2007 recall on the Sprint Fidelis electronic defibrillator leads, some patients are opting to have lead wires replaced.

Problems with Medtronic's Sprint Fidelis defibrillator wires were first brought to light in a March 2007 Dear Doctor Letter advising that the wire leads were prone to fracture. Reports of patient deaths and inappropriate patient shocks prompted the US FDA to issue a Class 1 Recall on the wire leads in October 2007.

There are still thousands of patients who have Medtronic's Sprint Fidelis leads left wondering if they should leave the wire lead in place and hope it does not fail or whether to have it extracted, sometimes at their own expense. Medtronic is limiting its contribution to wire lead removals to $800.00 for a procedure that can cost $12,500.00, and insurance companies appear to be dealing with coverage on a case-by-case basis.

The lead is a thin plastic tube enclosing electrical wires and sensors. The risks associated with surgical removal, besides the possibility for infection, include potential perforation of the heart and the veins in the chest. There is also a slight danger of damaging the heart valve through which the lead is threaded.


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer